** Shares of cell therapy developer Arcellx rise 8% to $91.35 premarket
** Co says its cell therapy anito-cel showed 97% overall response rate in a mid-stage trial testing patients with multiple myeloma, a type of blood cancer
** Overall response rate is the proportion of patients who have a partial or complete response to the therapy
** If approved, anito-cel, developed in partnership with Gilead , will compete with Johnson & Johnson's cell therapy Carvykti
** Brokerage TD Cowen says anito-cel's efficacy remains at least as good as Carvykti, but with superior safety
** ACLX's therapy showed no delayed damage to the nervous system, but three deaths occurred due to adverse events during the trial
** Up to last close, stock up 52.3% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。